Clopidogrel hypersensitivity: A novel multi-day outpatient oral desensitization regimen

Annals of Pharmacotherapy

Volumn 44, Issue 1, 2010, Pages 11-18

  Fajt, Merritt ^a   Petrov, Andrej ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac stent treatment; Clopidogrel hypersensitivity; Drug desensitization

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; TICLOPIDINE; WARFARIN;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DESENSITIZATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERSENSITIVITY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; TICLOPIDINE;

EID: 74549151070     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M379     Document Type: Article

References (50)

1. Grines CL, Bonow RO, Casey DE Jr, et al.; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-8. Epub 15 Jan 2007. DOI 10.1161/CIRCULATIONAHA.106. 180944
2. Becker RC, Meade TW, Berger PB, et al., American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:776S-814S. DOI 10.1378/chest.08-0685
3. Pinto Slottow TL, Steinberg DH, Roy PK, et al. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 2008;102:298-303. Epub 29 May 2008. DOI 10.1016/j.amjcard.2008.03.055
4. Product information. Plavix (clopidogrel bisulfate). New York, NY: Bristol-Myers Squibb Company & Sanofi-Synthelabo, August 2008.
5. Nebeker JR, Virmani R, Bennett CL, et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81. Epub 1 Dec 2005. DOI 10.1016/j.jacc.2005.07.071
6. Walker NE, Fasano MB, Horwitz PA. Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. J Invasive Cardiol 2006;18:341- 4.
7. Khambekar SK, Kovac J, Gershlick AH. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues. Heart 2004;90:e14-6. DOI 10.1136/hrt.2003.027367
8. Lee-Wong M, Gadhvi D, Resnick D. Clopidogrel desensitization (letter). Ann Allergy Asthma Immunol 2006;96:756-7.
9. Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005;65:525-7. DOI 10.1002/ccd.20433
10. Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose (letter). Int J Cardiol 2004;95:333. DOI 10.1016/j.ijcard.2003.03.023
11. Sarrot-Reynauld F, Bouillet L, Bourrain JL. Severe hypersensitivity associated with clopidogrel (letter). Ann Intern Med 2001;135:305-6.
12. Makkar K, Wilensky RL, Julien MB, Herrmann HC, Spinler SA. Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents. Ann Pharmacother 2006;40:1204-7. Epub 9 May 2006. DOI 10.1345/aph.1G587
13. Satish B, Tressa K, Harish CR. Case report on clopidogrel rash after coronary placement of a paclitaxol-coated stent. Crit Pathw Cardiol 2007;6:24-5. DOI 10.1097/01.hpc.0000255061.30935.f4
14. Fischer TC, Worm M, Groneberg DA. Clopidogrel-associated angioedema (letter). Am J Med 2003;114:77-8. DOI 10.1016/S0002-9343(02)01311-6
15. Andres E, Perrin AE, Alt M, Goichot B, Schlienger JL. Febrile pancytopenia associated with clopidogrel. Arch Intern Med 2001;161:125. DOI 10.1001/archinte.161.1.125
16. Doogue MP, Begg EJ, Bridgman P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc 2005;80:1368-70. DOI 10.4065/80.10.1368
17. Andersohn F, Hagmann FG, Garbe E. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 2004;90:e57-9. DOI 10.1136/hrt.2004.039214
18. Manor SM, Guillory GS, Jain SP. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy 2004;24:664-7. DOI 10.1592/phco.24.6.664.34732
19. Moy B, Wang JC, Raffel GD, Marcoux JP 2nd. Hemolytic uremic syndrome associated with clopidogrel: a case report. Arch Intern Med 2000;160:1370-2. DOI 10.1001/archinte.160.9.1370
20. Chinnakotla S, Leone JP, Fidler ME, Hammeke MD, Tarantolo S. Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. Transplantation 2000;70:550-2. DOI 10.1097/00007890-200008150-00029
21. Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization protocol (letter). Catheter Cardiovasc Interv 2007;69:154. DOI 10.1002/ccd.20919
22. Owen P, Garner J, Hergott L, Page RL II. Clopidogrel desensitization: case report and review of published protocols. Pharmacotherapy 2008;28:259-70. DOI 10.1592/phco.28.2.259
23. Oppedijk B, Odekerken DA, van der Wildt JJ, Melissant CF. Rapid oral desensitisation procedure in clopidogrel hypersensitivity. Neth Heart J 2008;16:21-3.
24. Walker NE, Fasano MB, Hobbs RA, Horwitz PA. Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity. Crit Pathw Cardiol 2007;6:26-9. DOI 10.1097/01.hpc.0000256476.82317.77
25. Kammer RT. Successful clopidogrel desensitization after drug-eluting stent implantation. J Invasive Cardiol 2009;21:134-5.
26. Vigo PG, MacDowell AL, Wedner HJ. Successful desensitization with clopidogrel after a positive skin test (abstract 44). Ann Allergy Asthma Immunol 2005;94:132-3.
27. von Tiehl KF, Price MJ, Valencia R, Ludington KJ, Teirstein PS, Simon RA. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007;50:2039-43. DOI 10.1016/j.jacc.2007.08.016
28. Celik G, Pichler W, Adkinson NF Jr. Drug allergy. In: Adkinson NF Jr, Yunginger J, Busse W, et al., eds. Middleton's allergy: principles and practice. 7th ed. Philadelphia: Elsevier Inc., 2008:1205-26.
29. Turvey SE, Cronin B, Arnold AD, Dioun AF. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004;92:426-32. DOI 10.1016/S0091-6749(03)81035-7
30. Gruchalla RS. Acute drug desensitization. Clin Exp Allergy 1998;28 (S4):63- 4.
31. Gruchalla RS, Pirmohamed M. Clinical practice. Antibiotic allergy. N Engl J Med 2006;354:601-9.
32. Lokhandwala J, Best P, Butterfield J, et al. Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel. Circ Cardiovasc Interv 2009;2:348-51. DOI 10.1161/CIRCINTERVENTIONS.108.832964.108.832964
33. Product information. Effient (prasugrel). Indianapolis: Eli Lilly and Co., July 2009.
34. Bhatt DL. Prasugrel in clinical practice. N Engl J Med 2009;361:940-2. DOI 10.1056/NEJMp0806848
35. Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119:2758-64. DOI 10.1161/ CIRCULATIONAHA.108.833665
36. Hannaway PJ, Hopper GD. Severe anaphylaxis and drug-induced beta-blockade (letter). N Engl J Med 1983;308:1536.
37. Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol 1988;81:1-5. DOI 10.1016/0091-6749(88)90212-6
38. Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med 1991;115:270-6.
39. Lang DM. Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf 1995;12:299-304. DOI 10.2165/00002018-199512050-00002
40. Goddet NS, Descatha A, Liberge O, et al. Paradoxical reaction to epinephrine induced by beta-blockers in an anaphylactic shock induced by penicillin. Eur J Emerg Med 2006;13:358-60. DOI 10.1097/01.mej.0000217993.09364. 35
41. Product information. Clopidogrel oral suspension. Nashville, TN: Vanderbilt University Hospital Prescription Compounding Centers of America (PCAA), January 2003.
42. Campbell K, Mallya R, Jaffrani W, et al. Treatment of clopidogrel hypersensitivity without drug interruption. Presented at: 58th Scientific Sessions. American College of Cardiology, 2009.
43. Adkinson NF Jr. Desensitization for drug hypersensitivity. J Allergy Clin Immunol 2008;122:581-2. DOI 10.1016/j.jaci.2008.07.020
44. Solensky R. Drug desensitization. Immunol Allergy Clin N Am 2004; 24:425- 43. DOI 10.1016/j.iac.2004.03.008
45. Tillman DJ, Charland SL, Witt DM. Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization. Arch Intern Med 2000;160:2926-32. DOI 10.1001/archinte.160.19. 2926
46. Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002;122:108-14. DOI 10.1378/chest. 122.1.108
47. Huse DM, Cummins G, Taylor DC, Russell MW. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation. Am J Manag Care 2002;8(1 suppl):S10-6.
48. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004;125:1642-50. DOI 10.1378/chest.125.5.1642
49. Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ. Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics 2000;18:451-7. DOI 10.2165/00019053-200018050-00004
50. Yong C, Fisher DA, Sklar GE, Li SC. A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective. Int J Antimicrob Agents 2009;33:46-51. DOI 10.1016/j.ijantimicag.2008.07.016